الهيدروكسي يوريا في علاج فقر الدم المنجلي
Abstract
تهدف هذه الدراسة إلى إظهار فوائد الهيدروكسي يوريا المخبرية والسريرية في علاج فقر الدم المنجلي، وقد شملت هذه الدراسة (50) مريضاً مصاباً بفقر الدم المنجلي ممن تعرضوا لثلاث نوب ألمية أو أكثر في العام السابق للدراسة، أو خضعوا لنقل دم متكرر أو استشفاء متكرر ( ثلاث مرات سنوياً على الأقل ) أو تعرضوا لنشبة دماغية أو متلازمة صدر حادة أو تشظي طحال، أو يعانون من فقر دم شديد عرضي.
تم البدء بالعلاج بجرعة ابتداءً من 15 مغ / كغ يومياً حتى30 مغ / كغ / يومياً، وقد تمت مراقبة هؤلاء المرضى كل 3 أشهر مخبرياً وسريرياً ( لمدة عام )، وأظهرت النتائج التحسن المخبري الملحوظ في قيم / HBF - MCV - HB / مع الانخفاض الواضح في قيمHBS وكذلك حدث تحسن سريري من خلال انخفاض معدل تكرر النوب الألمية، ومعدل نقل الدم ولكن كان عدد المرضى غير المستجيبين لهذا العلاج هو (5) مرضى إذ لم ترتفع نسبة الخضاب الجنيني لديهم إلى 15 % بعد عام كامل من العلاج.
This study aims to assess the laboratory and clinical benefits of hydroxyurea in the treatment of sickle cell disease. This study includes (50 ) patients of SCD who had reported at least three painful crises in the previous year, or had reported at least three transfusions or hospitalization in a year, or who had a history of stroke, acute chest syndrome or splenic sequestration, or who had systemic sever anemia. Hydroxyurea was gradually increased from an initial dose of 15 mg / kg / d to 30 mg / kg / d.
These patients were monitored by 3-month visits for one year to assess laboratory changes and clinical efficacy. Significant hematologic changes included increase in (HB - MCV- HBF) and decrease in HBS. And there was decrease in the number of transfusions, and painful crises. However, there were five patients who did not show any response to the treatment and the HBF concentration did not increase more than 15 % after a treatment for one year.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.